Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$2.14 - 2.15
Lot's of transactions going through at that third decimal. Seems to be higher than normal. The range is being kept tight.
Is it possible the ~$2.15 number is the agreed to pricepoint for a partner to take a stake in PPHM? And the flow of shares is being done with the ATM? But would that explain why there has not been any SEC documents filed for said transaction? This $2.15 price range is in Day 9 now. Surely it is beyond the given timeline to shed such a release. Highly unusual considering all the outside forces that control the stock price.
Though my Loof guess is 2/18 I am strongly considering 1/25 to be a crucial day in the history of Peregrine. My grandfather would get an ache in his knee just before the weather was about to change in a BIG way. Possibly we are watching the clouds forming and wind direction changing in front of our own eyes.
Threshold benefiting from Abraxane results. THLD up 20%. PPHM is getting played with this morning.
Recall, Eyebuystox' comparison with THLD partnership timing. It may not be exact, but that is the pattern PPHM will follow.
I don't know if I would equate attendance to the Roth Conference as not having a partner or partners in the works. There are a variety of reasons to attend the conference.
Loof is right; volume is trending upward albeit only the third day of the trend. But, it's a reversal of the trend since the Jan 7 PR about NSCLC data.
Guessing $2.15 close. It seems to be a magical number these days. Sure would like to know why.
On the otherhand, "the chart is looking like a breakout is about to happen..."
We keep track of the firm's "predictions." So far, in 2012 there is a 32% accuracy. Of course, some predictions have not materialized yet so it could get worse. In different times, when the internet was non-existant, that kind of journalism would not have been considered worthy of fish wrap! Maybe a dog owner would have used it to line the kennel.
We call it exponential from where I am from.
Still fascinated how we have kept close to $2.15 for days now.
$2.15
Starting to wonder what is so special about $2.15 that the pressure is on to keep it there.
These "journalists" do nothing to help the retail investor.
Relatively light volume. As some have said, "the calm before the storm." The trading range continues to tighten while volume lightens. The daily pattern we are seeing is wearing thin. But, it foretells how the risk - even within the window of a day - becomes too high to short this stock.
EYEBUYSTOX, I still think you hit the proverbial nail on the head with your comparison with Threshold. The timing of it and all. But Bavi's data may be more powerful. Next week we could know if you called it right.
Correct. The concern is not about getting a positive deal to move PPS. If Bavi is relevant, that will happen. The concern is more about lack of business savvy. Afterall, we are talking about someone who is more lab-oriented than business-oriented in King's case. Lytle's contract history can be of concern as well. The best case scenario is for them to get plenty of outside advice in the matter. Most times, the business talent of a $40 Billion pharmaceutical outweighs that of one that is $250 Million.
Concern should not be placed on whether the Bavi trial or trials are significant enough to proceed with a partner. Concern is more lined with how good a deal King and Lytle can negotiate. That, to me, is the difference between a jump to $5 and a jump to $12.
Still consolidating between $2.10 and $2.20. The base continues to get stronger. Now for some news.
Cup and handle forming in it's last stage. Not enough volume to finalize it though.
Nyk1, correct me if I'm wrong but are you trying to say the gap fill will be $1.40 from here? Seems to be the best explanation. So, the gap fill will be $2.10 + $1.40 = $3.50. You might be on to something...or on something.
Base forming between 2.10 and 2.20 with decent volume. The post-news sell off bottomed out and we could enjoy this buying opportunity for a few more days until the next step up.
$2.10 wall is slowly chipping away. Need some reinforcements or it drops to $2 - and maybe below.
Very possible. 80+ million shares in one day is surely activity where institutions are clamoring to get on board.
Having lived through the THLD data and sold too soon before the Roche announcement, I am holding on here.
Would you not think the partnership was already locked in? Peregrine was almost there in September. Why would a potential partner cut ties completely while Peregrine was evaluating the vials? They wouldn't. Similar to the Threshold partnership with Roche; release of data, then PR of partnership.
Revisiting EYEBUYSTOX' comparison with the THLD activity from 2012 one can expect a slight ramp up today and tomorrow with some pullback over the next two weeks. 1/21 is a holiday so most likely we get partner news on 1/22 - and another huge step up?
Day trader shorts covering for the day. Look for step up tomorrow.
Still anticipating fast track status.
Good call on THLD EYEBUYSTOX.
3:30 surge towards HOD is about to take place.
There is little doubt about partnership.
$5.50 PPS without a confirmed partnership. $10 PPS with one - hook, line and sinker?
"ultimately erroneous" may imply a negative, but the data could be in error and show better results than before.
Still focusing on the FDA fast track.
A carefully guided landing to $1.25 on the last tick of the day. Predictable. Once it is let loose of it's reigns PPHM will start the great incline up the mountain.
And the share price was probably, what, 70c then? Get real!
Consider this as summary of events:
NSCLC Phase II trial data was successfully reconfigured and the results judged to be better than originally released. Management then went back to the nearly-locked-in-partner with the results and opted to use the added leverage to negotiate a more beneficial contract, or, better yet, opened it back up to all contestants. Meanwhile, management recognized the timeline to start the bid process from the very beginning and opted to do an ATM to keep the company cash-flow positive. While we complain about the amount of dilution it is causing, the dollar amount was deliberate because Peregrine decides to work with the FDA in parallel while partnership negotiations take place - knowing this could take significant time and resources (thus the new hiring). Management deems the leverage to be even greater if FDA is on the cusp of approving Phase III. The partner-to-be was also interested in partnering for Cotara and meanwhile Cotara gets approved for PIII. Management has opted to keep the Cotara partnership open as further leverage in case the nearly-locked-in-partner ends up the highest bidder - thus the need for the ATM. SK pays back the loan "early" and the default amount knowing the responsible third party vendor will compensate for lost damages.
More and more, the lies brought on by the firm prove they are not even on the same level as our GJH, FTM, CL and others are. Splendid and exciting times ahead for PPHM!
100% agreement RRdog. You nailed it - specifically point #2.
Analysts are not calling Peregrine a hoax. One puppet with a loud voice is calling the company a hoax. But his firm is filled with fraud so how reliable is what he says?
you think????!!!
This might be why:
http://www.bloomberg.com/news/2012-12-18/sec-sues-thestreet-com-ex-cfo-ashman-over-accounting.html
Fraudulent firm all around...
Enough about the 3 member BOD. Maybe when the value of PPHM is $500 M or greater they can/should expand it to 4 or 5. Then, when valuation reaches $1 Billion go to 6-7 members. And then your wish of 9 can be granted when it's $5 Billion.
Interim allows for the possibility of announcing results along with partnership.
Below radar 4900 share trades crossing. Good sign of end of day rally.
Drunk cowboy and bigfoot need to remove the bungee cords. That is what is bringing the rocketship back. Let 'er rip!
First FDA "Breakthrough"
Quite possibly the real reason for the stock price increase 10 days ago.
Surprised you're surprised.
My favorite line:
Peregrine's senior management will discuss financial results for the second quarter of fiscal year ended October 31, 2012 and will review progress of its clinical development programs.
Can someone advise what an "ancient brain tumor" is.